Navigation Links
EGT Transfers cGMP Vector for Gene Therapy Trial
Date:7/29/2011

CHICAGO, July 29, 2011 /PRNewswire/ -- Errant Gene Therapeutics, LLC ("EGT"), a pioneering boutique drug development firm specializing in Rare Diseases, announced the transfer of its clinical grade lentiviral vector, TNS 9.55.3, to Memorial Sloan Kettering Cancer Center ("MSKCC"). TNS 9.55.3  developed by EGT pursuant to an exclusive license agreement with Sloan Kettering Institute (SKI), will be used for MSKCC's upcoming beta Thalassemia human clinical trial. The trial protocol provides for the "in vitro" treatment of beta-thalassemia patients, offering the prospect for a cure for a chronic condition which would otherwise subject the patient to early death without incurring life-long regular blood transfusions and chelation therapy.

A new definitive agreement between EGT and SKI provides for MSKCC to lead the clinical trials and arrange for drug development partnerships for the treatment of beta-Thalassemia and Sickle Cell Disease, two of the worlds most prevalent and devastating hereditary blood conditions.  

EGT continues its decade's long commitment to cure beta-Thalassemia, also called Cooley's Anemia, through dedicated outreach to patient and research communities around the world. Pat Girondi, EGT founder and CEO, stated, "the pioneering research of SKI's Sadelain team is positioned to deliver the safest and most effective cure for the many millions of patients whose hopes and prayers we have honored with our total dedication." EGT received protocol approval for the upcoming trials by unanimous vote of the Recombinant DNA Advisory Committee of the NIH in 2007, and was granted orphan drug designation by both the FDA and the EMEA. The clinical trial is expected to commence in the fourth quarter of 2011.

Sam Salman, EGT's president said that with "MSKCC and SKI taking the lead in the clinical and developmental activities for TNS 9.55.3, EGT will be able to further progress its pre-clinical programs for its novel drug cancer therapies targeting chronic hormone refractory cancers."  

About Errant Gene Therapeutics, LLC

Errant Gene Therapeutics ("EGT") is a privately held biopharmaceutical company established in 2003. In addition to its ongoing support of gene therapy for the cure of beta-thalassemia and Sickle Cell Anemia, EGT is a pioneer in the emerging field of epigenetics focused on the treatment of deadly hormone  refractory cancers using its patented portfolio of small molecule histone deacetylases inhibitors (HDACi). EGT's lead HDACi, CG-1521, targets Inflammatory Breast Cancer and Hormone Refractory Prostate Cancer.

For more information about EGT and its programs, please visit www.errantgene.com.


'/>"/>
SOURCE Errant Gene Therapeutics, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CardioGenics Transfers Magnetic Beads Business Unit Into its Luxspheres Inc. Subsidiary
2. Scottish Executive Awards Varian Medical Systems Major Contract to Supply Advanced Radiotherapy Equipment to Scotlands Five Cancer Centers
3. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
4. Arkansas Researcher is Exploring MR-Guided Focused Ultrasound as an Adjuvant Therapy to Radiation
5. Mail-Order Pharmacy for New Statin Prescriptions Achieve Better Cholesterol Control in First 3-15 Months of Therapy
6. Provent® Sleep Apnea Therapy Now Available in India
7. OrbusNeichs Genous™ Stent Enables Early and Safe Discontinuation of Dual Antiplatelet Therapy in High-Risk Patients Requiring Nondeferrable, Non-Cardiac Surgery
8. New Release of Elektas Monaco Treatment Planning System Prepares Software for Stereotactic Radiation Therapy
9. Latest Releases of Elektas XiO Planning and Focal Contouring Systems Designed to Increase Efficiency in Planning Therapy for Patients with Cancer
10. Dehaier Opens First Oxygen Filling Facility and First Service Center for Home Oxygen Therapy Service in Beijing
11. PhotoMedexs Itching to Win Contest Offers Free Phototherapy Treatments With the XTRAC Laser to Deserving Psoriasis Patients Nationwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... -- Story Highlights: , ... health care industry is causing providers to review operating ... offers a suite of solutions for health care providers ... optimization: labor resource analysis, revenue cycle optimization and physician ... and better economics ...
(Date:6/24/2016)... 24, 2016  Collagen Matrix, Inc., ("Collagen Matrix") ... manufacturing of collagen and mineral based medical devices ... Bill Messer has joined the company ... leverage the growing portfolio of oral surgery, neurosurgery, ... Bill joins the Collagen Matrix executive team as ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
Breaking Medicine News(10 mins):